https://scholars.lib.ntu.edu.tw/handle/123456789/520967
標題: | Subgroup identification for treatment selection in biomarker adaptive design Data analysis, statistics and modelling | 作者: | TZU-PIN LU Chen J.J. |
公開日期: | 2015 | 出版社: | BioMed Central Ltd. | 卷: | 15 | 期: | 1 | 來源出版物: | BMC Medical Research Methodology | 摘要: | Background: Advances in molecular technology have shifted new drug development toward targeted therapy for treatments expected to benefit subpopulations of patients. Adaptive signature design (ASD) has been proposed to identify the most suitable target patient subgroup to enhance efficacy of treatment effect. There are two essential aspects in the development of biomarker adaptive designs: 1) an accurate classifier to identify the most appropriate treatment for patients, and 2) statistical tests to detect treatment effect in the relevant population and subpopulations. We propose utilization of classification methods to identity patient subgroups and present a statistical testing strategy to detect treatment effects. Methods: The diagonal linear discriminant analysis (DLDA) is used to identify targeted and non-targeted subgroups. For binary endpoints, DLDA is directly applied to classify patient into two subgroups; for continuous endpoints, a two-step procedure involving model fitting and determination of a cutoff-point is used for subgroup classification. The proposed strategy includes tests for treatment effect in all patients and in a marker-positive subgroup, with a possible follow-up estimation of treatment effect in the marker-negative subgroup. The proposed method is compared to the ASD classification method using simulated datasets and two publically available cancer datasets. Results: The DLDA-based classifier performs well in terms of sensitivity, specificity, positive and negative predictive values, and accuracy in the simulation data and the two cancer datasets, with superior accuracy compared to the ASD method. The subgroup testing strategy is shown to be useful in detecting treatment effect in terms of power and control of study-wise error. Conclusion: Accuracy of a classifier is essential for adaptive designs. A poor classifier not only assigns patients to inappropriate treatments, but also reduces the power of the test, resulting in incorrect conclusions. The proposed procedure provides an effective approach for subgroup identification and subgroup analysis. ? 2015 Lu and Chen. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949553114&doi=10.1186%2fs12874-015-0098-7&partnerID=40&md5=97eeb9b44125c0bf1896af8b9ad8ef75 https://scholars.lib.ntu.edu.tw/handle/123456789/520967 |
ISSN: | 1471-2288 | DOI: | 10.1186/s12874-015-0098-7 | SDG/關鍵字: | tumor marker; adenocarcinoma; algorithm; bioassay; computer simulation; disease free survival; human; Lung Neoplasms; methodology; patient selection; personalized medicine; procedures; statistical model; Adenocarcinoma; Algorithms; Biomarkers, Tumor; Computer Simulation; Disease-Free Survival; Endpoint Determination; Humans; Lung Neoplasms; Models, Statistical; Patient Selection; Precision Medicine; Research Design |
顯示於: | 流行病學與預防醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。